MIF and neoplasm: Thus, the seemingly controversial result regarding MIF could be partially explained by the use of different tumor models and mouse strains, since BALB/c mice harbor an inactivating mutation of the cyclin-dependent kinase inhibitor p16INK4a [88], which increases the risks of associated cell-cycle alterations in KC.